CatalystMarker
← board

CYRX

distress 0/10 · well-funded / low risk
$16.45+0%today-1% from 52w high
cryoportinc.com684 employeesFounded 1999Brentwood, TNIntegrated Freight & Logistics
Revenue
$48M
Liquidity
$404M
Runway
802.5 yrs
Shares 1y
+1%

Price & events

+50.5% over 6M
$7.72$12.14$16.57Jan 26Apr 26Jul 262.7Mrating: Craig-Hallum: Buy (2026-06-03)rating: Keybanc: Overweight (2026-05-20)rating: Guggenheim: Buy (2026-05-05)rating: BTIG: Buy (2026-05-05)rating: Needham: Buy (2026-05-05)rating: Craig-Hallum: Buy (2026-03-30)rating: Needham: Buy (2026-03-04)
CatalystRating changeDilutionFinancingdashed = today
+0.2%
1D
-0.3%
1W
+11.4%
1M
+61.7%
3M
+58.3%
6M
+110.6%
1Y
+82.1%
2Y
-72.5%
5Y
-65.0%
All

Overview

Market Cap
$828.87M
Volume
31.46K
52 Week Range
$6.71 – $16.57
Total Shares
50.40M
Float Shares
40.85M
Short %
5.21%
% Held by Insiders
3.93%
% Held by Institutions
96.11%
RVOL
0.04x
Beta
1.89

Pipeline · 0 trials · 0 upcoming

ReadoutPhaseDrugIndicationEnrollStatus
No pipeline trials tracked.

Catalyst news & presentations · 4

Approved drugs (0)

  • none — clinical-stage

Capital structure — dilution & financing

Shares out: 50,402,313 · 0 offerings/1y · 0 PIPEs
🔒 Positioning — Pro
Short interest / days-to-cover, insider buys & sells.
Upgrade to Pro
🔒 Top holders — Pro
Institutional ownership + quarter-over-quarter accumulation/trimming.
Upgrade to Pro

Wall St ratings

no consensus
  • 2026-06-03Craig-HallumBuy
  • 2026-05-20KeybancOverweight
  • 2026-05-05GuggenheimBuy
  • 2026-05-05BTIGBuy
  • 2026-05-05NeedhamBuy
  • 2026-03-30Craig-HallumBuy

Competitors

  • none identified

Not financial advice. Data: ClinicalTrials.gov, SEC EDGAR, FINRA, Nasdaq, Yahoo.